Clinical care of children and adolescents with COVID-19: recommendations from the National COVID-19 Clinical Evidence Taskforce.
David Fraile NavarroBritta TendalDavid TingayNan VasilunasLorraine AndersonJames BestPenelope BurnsSaskia CheyneSimon S CraigSimon J EricksonNicholas Ss FancourtZoy GoffVimbai KapuyaCatherine KeyteLorelle MalyonSteve McDonaldHeath WhiteDanielle WurzelAsha C BowenBrendan McMullannull nullPublished in: The Medical journal of Australia (2021)
The Taskforce currently recommends corticosteroids as first line treatment for acute COVID-19 in children and adolescents who require oxygen. Tocilizumab could be considered, and remdesivir should not be administered routinely in this population. Non-invasive ventilation or high flow nasal cannulae should be considered in children and adolescents with hypoxaemia or respiratory distress unresponsive to low flow oxygen if appropriate infection control measures can be used. Children and adolescents with PIMS-TS should be managed by a multidisciplinary team. Intravenous immunoglobulin and corticosteroids, with concomitant aspirin and thromboprophylaxis, should be considered for the treatment of PIMS-TS. The latest updates and full recommendations are available at www.covid19evidence.net.au.
Keyphrases
- coronavirus disease
- sars cov
- quality improvement
- palliative care
- healthcare
- low dose
- rheumatoid arthritis
- respiratory syndrome coronavirus
- high dose
- type diabetes
- liver failure
- venous thromboembolism
- cardiovascular disease
- clinical practice
- sensitive detection
- drug induced
- intensive care unit
- extracorporeal membrane oxygenation
- rheumatoid arthritis patients
- health insurance